CA-PATIENT-SAFETY
3.2.2020 15:02:07 CET | Business Wire | Press release
Patient Safety Movement Foundation is urging clinicians, patient advocates, hospitals and medical technology companies to support Data Sharing as part of the 2020 Federal Health IT plan.
“One of the key ways to combat preventable patient deaths in hospitals is for companies to share their data in a HIPAA compliant manner instead of hoarding it for profit. The plan proposed by the Office of the National Coordinator for Health Information Technology will help create the personalized patient data superhighway we need to reduce and eliminate preventable deaths in our hospitals,” said Joe Kiani, Founder of the Patient Safety Movement and Founder, Chairman, and CEO of Masimo. “If we block patient data, no one can create algorithms that can warn clinicians of potential problems before they happen. We are already losing way too many people to medical errors in our hospitals each year, and we can’t delay this any longer.”
Several years ago, a young man named Rory Staunton died of Sepsis because of exactly this type of fragmented medical information system. “On Tuesday, my son Rory was playing basketball at a school gym, fell and cut himself. His teacher put a bandaid on it. He died 5 days later from Sepsis,” said Orlaith Staunton. “Despite having a high heart rate for his size as measured by a patient monitor at his pediatrician’s office and a high white blood cell count that was detected in the Emergency Department’s blood test machine, Rory was sent home because no one had all of the details of his problems and care. They couldn’t put the high heart rate and high white blood cell count together with the full story to realize he had Sepsis. Had we had data sharing allowing a complete view of his history and condition or the benefit of a predictive algorithm to track my son’s case when he was connected to various monitors and blood test machines, he would probably be alive today.”
Since the founding of the Patient Safety Movement, nearly 100 companies have signed the voluntary Open Data Pledge, including Baxter, Cerner, Dräger, Edwards Lifesciences, GE Healthcare, IBM, Masimo, Medtronic, Oracle, Philips and Zoll. Complete list below. For more information on how you can sign the Pledge, please visit www.patientsafetymovement.org . For more information regarding the 2020 Federal Health IT Plan, please visit https://www.healthit.gov/sites/default/files/page/2020-01/2020-2025FederalHealthIT%20StrategicPlan_0.pdf .
Companies that have signed the Patient Safety Movement Foundation Open Data Pledge (alphabetical order):
AccuHealth Group |
Admetsys |
AirStrip |
Ambient Clinical |
Baxter |
BD Intelliport (formerly CRISI Medical Systems) |
Bernoulli Health |
Beterra Health |
BIOIN SOLUCIONES SAS |
Biovigil |
BrainStem Biometrics |
caresyntax, Inc. |
Cercacor |
Cerner |
Cheetah Medical, Inc. |
Clean Hands-Safe Hands |
CNSystems Medizintechnik AG |
Codonics |
CrossChx |
DebMed |
Decisio Health |
Deltex Medical |
Doctella |
Dräger |
DynaLabs LLC |
11 Health |
EarlySense |
eBroselow, LLC |
Edwards LifeSciences |
Forcare |
FUJIFILM SonoSite, Inc. |
GE Healthcare |
Genomi-k |
Hamilton Medical AG |
Handtevy-Pediatric Emergency Standards, Inc. |
Healthcentrix |
Heartin Inc. |
HeROScore |
Hiteks |
IBM Watson Health |
ICUcare |
Informs Inc. |
Innara Health |
Iradimed |
Jvion |
KnectIQ Inc. |
Kolkin |
LiDCO Group |
LumiraDX USA Inc. |
Magnamed Tecnologia Médica S/A. |
Masimo |
Mdoloris Medical Systems |
Medi+Sign |
Medical Simulation Corporation |
MediSafe Inc |
Medtronic |
Mindray |
Modulated Imaging |
Monarch Medical Technologies |
Neosim |
NeurOptics |
Oracle |
Patient Valet |
Pegwin |
PeraHealth |
PerceptiMed |
Philips Healthcare |
Phoenix Medical Systems Pvt. Ltd. |
Pieces Technology |
Pooyandegan Rah Saadat Co.,Ltd. |
Rapid Healthcare |
Redivus Health |
RGP Healthcare |
RightPatient |
RPRD Diagnostics |
SafeCare Group |
SafeStart Medical |
SenTec Inc. |
Smiths Medical |
Sotera Wireless |
Stanley Healthcare |
Stibo Systems |
SurgiCount Medical |
SwipeSense |
Talis Clinical |
ThermoMedics, Inc. |
Triton Electronic Systems LTD |
True Process |
Vitalacy (FORMERLY Hygenix) |
Welch Allyn (acquired by Hill-Rom) |
West-Com Nurse Call Systems, Inc |
ZOLL Medical |
About Patient Safety Movement Foundation
Each year, more than 200,000 people die unnecessarily in U.S. hospitals. Worldwide, 4.8 million lives are similarly lost. The Patient Safety Movement Foundation (PSMF) is a global non-profit that offers free tools to help achieve ZERO preventable deaths from hospital errors. The Patient Safety Movement Foundation was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare to reduce that number of preventable deaths to ZERO. Improving patient safety requires a collaborative effort from all stakeholders, including patients, healthcare providers, medical technology companies, government, employers, and private payers. PSMF’s World Patient Safety, Science & Technology Summit brings together the world’s best minds for thought-provoking discussions and new ideas to challenge the status quo. Our Actionable Patient Safety Solutions (APSS) provide evidence-based processes to help hospitals eliminate errors. Our Open Data Pledge encourages healthcare technology companies to share the data for which their products are purchased. Visit patientsafetymovement.org.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200203005118/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
